Artificial intelligence for radiomics; diagnostic biomarkers for neuro-oncology
1 Department of Diagnostic Radiology and Nuclear Medicine, Rush Medical College, Chicago, USA.
2 Goddard lab, Radiology department. Penn Medical University, Philadelphia, Pennsylvania, USA.
3 Department of Internal Medicine, Iran University of Medical Science, Tehran, Iran.
4 Department of Radiology, Ahwaz Jondishapour Medical University, Ahwaz, Iran.
Review Article
World Journal of Advanced Research and Reviews, 2022, 14(03), 304–310
Article DOI: 10.30574/wjarr.2022.14.3.0544
Publication history:
Received on 06 May 2022; revised on 11 June 2022; accepted on 13 June 2022
Abstract:
Recent advances in medical image analysis have been made to improve our understanding of how disease develops, behaves, and responds to treatment. Magnetic resonance imaging (MRI) and positron emission tomography (PET) advanced imaging strategies provide structural and functional phenotypic biomarkers that correlate with key disease processes.
Through radiomics and radiogenomics, ML-medical imaging has opened up new perspectives in high-grade glioma diagnosis. As a result, non-invasive and in vivo biomarkers for patient survival, tumor recurrence, and genomics are identified. Tumor genomic imaging signatures can help identify patients who benefit from targeted therapies. Molecular characterization of gliomas and prediction of their evolution would allow treatment optimization.
Radiomics-based biomarkers allow for a more in-depth analysis of pathophysiologic processes and insights into diagnosing better, classifying, stratifying, and prognosticating brain tumors and assessing their response to therapy. Radiomics is a new data-driven approach that can help answer clinical questions like diagnosis, prognosis, and treatment response. With encouraging outcomes in brain tumor patients, radiomics and deep learning are still not widely used in clinical practice, requiring more extensive and practical clinical studies.
Keywords:
Brain Tumor; Artificial Intelligence; Biomarkers; Radiology; Deep Learning; Cancer
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0